Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Canagliflozin slows the progression of chronic kidney disease in patients with type 2 diabetes and induces a reversible acute drop in estimated glomerular filtration rate (eGFR), believed to be a hemodynamic effect. Predictors of the initial drop and its association with long-term eGFR trajectories...

Full description

Bibliographic Details

Published in:	Kidney international Vol. 99; no. 4; p. 999
Main Authors:	Oshima, Megumi, Jardine, Meg J, Agarwal, Rajiv, Bakris, George, Cannon, Christopher P, Charytan, David M, de Zeeuw, Dick, Edwards, Robert, Greene, Tom, Levin, Adeera, Lim, Soo Kun, Mahaffey, Kenneth W, Neal, Bruce, Pollock, Carol, Rosenthal, Norman, Wheeler, David C, Zhang, Hong, Zinman, Bernard, Perkovic, Vlado, Heerspink, Hiddo J L
Format:	Journal Article
Language:	English
Published:	United States 01.04.2021
Subjects:	Canagliflozin - adverse effects Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Glomerular Filtration Rate Humans Renal Insufficiency, Chronic - diagnosis Sodium-Glucose Transporter 2 Inhibitors - adverse effects chronic kidney disease type 2 diabetes SGLT2 inhibitor canagliflozin
ISSN:	1523-1755, 1523-1755
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!